Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
| Preferred Name | Cerivastatin | |
| Synonyms |
|
|
| Definitions |
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65308 |
|
| CAS_Registry |
145599-86-6
|
|
| CHEBI_ID |
CHEBI:3558
|
|
| Chemical_Formula |
C26H34FNO5
|
|
| code |
C65308
|
|
| Contributing_Source |
FDA
|
|
| definition |
A synthetic lipid-lowering agent. Cerivastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing major histocompatibility complex II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells. Muscle toxicity (myopathy and rhabdomyolysis) precludes the clinical use of this agent.
|
|
| FDA_UNII_Code |
AM91H2KS67
|
|
| Has_Salt_Form | ||
| in_subset | ||
| label |
Cerivastatin
|
|
| Legacy Concept Name |
Cerivastatin
|
|
| Preferred_Name |
Cerivastatin
|
|
| prefixIRI |
NCIT:C65308
|
|
| prefLabel |
Cerivastatin
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0528023
|
|
| subClassOf |
Add comment
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |
Create mapping